C
Tier
Long-acting GHRH analog that boosts GH pulses.
Muscle & Performance
Peptide
WADA Status:
Prohibited at all times (S2)
Human Trial Scoreboard
Completed human RCTs
Count not verified
Largest Human Study
Size not verified
Longest exposure
Duration not verified
Most Recent Trial
Year not verified
Description
CJC-1295 is a modified version of the natural signal that tells the pituitary gland to release growth hormone. Developed by the Canadian company ConjuChem, it comes in two forms that are routinely and confusingly sold as one. The version with DAC, a drug affinity complex, carries an extra chemical group that binds it to albumin in the blood and stretches its effect over days. The version without DAC, usually sold as Mod GRF 1-29, lacks that group and acts briefly. They behave quite differently in the body. The DAC form reached mid-stage testing for HIV-associated fat redistribution in the mid 2000s before development stopped. Neither form was approved anywhere. Like the rest of its class, it reliably shifts a hormone level, which is a laboratory measurement rather than an outcome anyone experiences.
What Are The Claims
Claims made for this compound: Sustained rise in GH and IGF-1 (human PK data); Proposed better sleep, recovery, and body composition; Synergistic when stacked with ipamorelin
Evidence
The FDA's own briefing document is the most useful source here, because it states the agency's specific reservations: limited clinical data and reported serious adverse events including increased heart rate and a systemic vasodilatory reaction. Human data covers pharmacokinetics and growth hormone release. It does raise GH and IGF-1, and that is where the evidence stops. No trial has demonstrated that this translates into the body composition, recovery, or anti-aging outcomes it is sold for. Moving a hormone level and producing a clinical benefit are separate claims requiring separate evidence.
Evidence Strength
Preliminary (human PK/proof-of-concept only)
Caveats
No clinical-outcome trials; not FDA-approved; the studied DAC form differs from grey-market no-DAC.
Safety
Alternative Measures
Legal Status
US
Not approved; removed from restricted compounding category April 2026
UK
Not approved
EU
Not approved
AU
Not approved
WADA
Prohibited at all times (S2)
Not approved. Placed in FDA Category 2 in September 2023 and removed effective 27 September 2024 after the nomination was withdrawn. In April 2026 it was among the peptides formally removed from Category 2 without promotion to Category 1. At the October and December 2024 Pharmacy Compounding Advisory Committee meetings, the FDA recommended against adding it to the 503A list. WADA-prohibited.
Citations
FDA Pharmacy Compounding Advisory Committee briefing document (fda.gov/media/193343): limited clinical data, serious adverse events including increased heart rate and systemic vasodilatory reaction. | FDA 503A Category 2, September 2023; removed 27 September 2024. | FDA recommended against 503A inclusion, PCAC meetings October and December 2024. | WADA Prohibited List.